Method of treating infectious bursal disease virus infections
OwnerCraig E. Whitfill, John A. Thoma +3inventors
InventorsCraig E. Whitfill, John A. Thoma, Tommy L. Fredericksen, Julius K. Tyczkowski, J. Paul Thaxton, Jr.
Life of this patent
Estimating the term…
Abstract
A method of producing active immunity against infectious bursal disease virus in an avian subject comprises administering to the subject a vaccine complex consisting essentially of a live virus and a neutralizing factor bound to the live virus. The neutralizing factor is selected from the group consisting of antibodies and antibody fragments. The live virus is one capable of producing disease in the subject, and the antibody or antibody fragment is one capable of neutralizing the live virus. A preferred route of administration to birds is by in ovo administration.
Claims34
A method of producing active immunity against Infectious Bursal Disease Virus in an avian subject, comprising:
- administering to said subject at a time ranging from about the last quarter of in ovo incubation to about the first three days after hatch a vaccine complex, said vaccine complex comprising live infectious bursal disease virus and a neutralizing factor bound to said live virus,
- said live virus being a pathogenic virus capable of causing disease in said subject;
- said neutralizing factor selected from the group consisting of IgG immunoglobulins;
- which neutralizing factor neutralizes the live virus;
- said vaccine conjugate produced by the process of combining blood serum containing said neutralizing factor with said live virus;
- said vaccine complex administered in an amount effective to produce active immunity against infectious bursal disease virus in said subject.
A vaccine preparation useful for producing active immunity against Infectious Bursal Disease Virus in an avian subject, said vaccine preparation comprising:
- a pharmaceutically acceptable formulation comprising a vaccine complex;
- said vaccine complex further comprising live infectious bursal disease virus and a neutralizing factor bound to said live virus,
- said live virus being a pathogenic virus capable of causing disease in said subject;
- said neutralizing factor selected from the group consisting of IgG immunoglobulins;
- which neutralizing factor neutralizes said live virus;
- said vaccine complex produced by the process of combining blood serum containing said neutralizing factor with said live virus;
- said vaccine complex included in said pharmaceutically acceptable formulation in an amount effective to produce an active immune response to said live virus in said subject.
An article of manufacture comprising a closed, pathogen-impermeable container and a sterile vaccine preparation enclosed within said container, said vaccine preparation useful for producing active immunity against Infectious Bursal Disease Virus in an avian subject, said vaccine preparation comprising:
- a pharmaceutically acceptable formulation comprising a vaccine complex;
- said vaccine complex comprising a live infectious bursal disease virus and a neutralizing factor bound to said live virus,
- said live virus being a pathogenic virus capable of causing disease in said subject;
- said neutralizing factor selected from the group consisting of IgG immunoglobulins;
- which neutralizing factor neutralizes said live virus;
- said vaccine complex produced by the process of combining blood serum containing said neutralizing factor with said live virus;
- said vaccine complex included in said pharmaceutically acceptable formulation in an amount effective to produce an active immune response to said live virus in said subject.
A method of producing active immunity against Infectious Bursal Disease Virus in an avian, comprising:
- administering to said subject at a time ranging from about the last quarter of in ovo incubation to about the first three days after hatch a vaccine complex, said vaccine complex comprising live infectious bursal disease virus and a neutralizing factor bound to said live virus;
- said live virus, being a pathogenic virus capable of causing disease in said subject;
- said neutralizing factor selected from the group consisting of IgG immunoglobulins and IgG immunoglobulin fragments, and wherein said neutralizing factor is monoclonal in origin;
- which neutralizing factor neutralizes said live virus;
- said vaccine complex administered in an amount effective to produce active immunity against infectious bursal disease virus in said subject.
A vaccine preparation useful for producing active immunity against Infectious Bursal Disease Virus in an avian subject, said vaccine preparation comprising:
- a pharmaceutically acceptable formulation comprising a vaccine complex;
- said vaccine complex further comprising live infectious bursal disease virus and a neutralizing factor bound to said live virus;
- said live virus being a pathogenic virus capable of causing disease in said subject;
- said neutralizing factor selected from the group consisting of IgG immunoglobulins and IgG immunoglobulin fragments, and wherein said neutralizing factor is monoclonal in origin;
- which neutralizing factor neutralizes said live virus;
- said vaccine complex included in said pharmaceutically acceptable formulation in an amount effective to produce an active immune response to said live virus in said subject.
An article of manufacture comprising a closed, pathogen-impermeable container and a sterile vaccine preparation enclosed within said container, and vaccine preparation useful for producing active immunity against Infectious Bursal Disease Virus in an avian subject, said vaccine preparation comprising:
- a pharmaceutically acceptable formulation comprising a vaccine complex;
- said vaccine complex further comprising live infectious bursal disease virus and a neutralizing factor bound to said live virus;
- said live virus being a pathogenic virus capable of causing disease in said subject;
- said neutralizing factor selected from the group consisting of IgG immunoglobulins and immunoglobulin fragments, and wherein said neutralizing factor is monoclonal in origin;
- which neutralizing factor neutralizes said live virus;
- said vaccine complex included in said pharmaceutically acceptable formulation in an amount effective to produce an active immune response to said live virus in said subject.
Dependencies are inferred from the claim text.